Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT-001 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Malignant melanoma; Merkel cell carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Transgene

Most Recent Events

  • 22 Jul 2024 According to a BioInvent International media release, company announced initial results from this trial for BT-001 has been selected for presentation at ESMO 2024, being held in Barcelona, Spain from September 13th to 17th, 2024.
  • 31 Jan 2024 This trial has been completed in France.
  • 10 Oct 2023 According to a Transgene media release, first patient of the Phase I part B has been dosed and inclusion of the last patient in Part B of the study is expected in H1 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top